



an Open Access Journal by MDPI

Anticancer Metal-Based Compounds

Guest Editor:

Dr. Manos Vlasiou

Department of Veterinary
Medicine, University of Nicosia
School of Veterinary Medicine,
2414 Nicosia, Cyprus

Deadline for manuscript
submissions:

30 November 2024

Message from the Guest Editor

This Special Issue of *Biomedicines* explores the latest advancements in the field of anticancer metal-based compounds. Metal-based compounds have long been recognized for their potential in cancer treatment due to their diverse chemical properties and unique mechanisms of action. This Special Issue features a collection of original research articles, mini reviews, comprehensive reviews, theoretical studies, and perspectives from leading experts in this field, providing insights into the design, synthesis, characterization, and therapeutic applications of metal-based compounds for cancer treatment.

Overall, this Special Issue provides a comprehensive overview of the current state-of-the-art research on anticancer metal-based compounds and highlights their potential as promising candidates for the development of next-generation cancer therapeutics.



mdpi.com/si/204129

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI